← Back to Search

Checkpoint Inhibitor

atezolizumab for Melanoma

Phase 1 & 2

Waitlist Available

Research Sponsored by Lokon Pharma AB

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from treatment initiation until last patient last visit, assessed up till 36 months

Awards & highlights

Study Summary

This trial will test the safety and efficacy of combining an oncolytic adenovirus (a virus that kills cancer cells) with atezolizumab in patients with melanoma.

Eligible Conditions

Melanoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from treatment initiation until last patient last visit, assessed up till 36 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from treatment initiation until last patient last visit, assessed up till 36 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and from treatment initiation until last patient last visit, assessed up till 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of patients with toxicities

Secondary outcome measures

Antibodies against LOAd703

Immune cell phenotype

Overall response rate

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: TreatmentExperimental Treatment2 Interventions

Delolimogene mupadenorepvec plus atezolizumab

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

atezolizumab

2016

Completed Phase 2

~160

delolimogene mupadenorepvec

2020

Completed Phase 2

~30

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Precision Oncology LLCUNKNOWN

Lokon Pharma ABLead Sponsor

2 Previous Clinical Trials

101 Total Patients Enrolled

Angelica Loskog, PhDStudy ChairLokon Pharma AB

3 Previous Clinical Trials

116 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How is atezolizumab being utilized to alleviate symptoms?

"Atezolizumab is commonly prescribed for the treatment of small cell lung cancer, but also shows promise in managing postoperative malignant neoplasms and non-small cell lung carcinomas."

Answered by AI

Has any similar research been conducted on this topic prior to now?

"Presently, there are 351 active studies for the drug atezolizumab that span 74 countries and 1645 cities. This medication has received clinical attention since 2008 when Hoffmann-La Roche sponsored a Phase 2 trial involving 720 participants; this study marked the beginning of 80 completed trials to date."

Answered by AI

Is enrollment currently underway for this trial?

"Affirmative. According to the information stored on clinicaltrials.gov, this medical trial is currently seeking participants. It was initially posted on January 28th 2020 and recently updated on April 4th 2022; 35 people are needed from two seperate sites for enrollment in the trial."

Answered by AI

Are there any historical precedents of research with atezolizumab?

"Atezolizumab was first introduced to clinical trials by SCRI Tennessee Oncology Chattanooga in 2008, with 80 studies completed since then. Currently, there are 351 live experiments taking place across the world—a noteworthy amount of these based in Los Angeles."

Answered by AI

What is the current participant count for this trial?

"Affirmative, the clinicaltrials.gov platform attests to this trial being actively recruitment candidates. It was initially posted on January 28th 2020 and then updated most recently on April 4th 2022. The participation of 35 patients needs to be secured from 2 specialized sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

2020. "A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04123470.